MedPath

AM-101 in the Treatment of Post-Acute Tinnitus 1

Phase 3
Completed
Conditions
Tinnitus
Interventions
Drug: AM-101
Registration Number
NCT01934010
Lead Sponsor
Auris Medical, Inc.
Brief Summary

The purpose of this research study is to test the safety and local tolerance of repeated treatment cycles of AM-101.

Detailed Description

This open-label extension study is assessing the safety and local tolerance of repeated treatment cycles of AM-101 in subjects previously treated in the scope of the TACTT2 study (NCT01803646).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
260
Inclusion Criteria
  • Completion of TACTT2 study;
  • Negative pregnancy test (woman of childbearing potential);
  • Willing and able to attend the study visits during at least one treatment cycle.

Other protocol-defined inclusion criteria may apply.

Exclusion Criteria
  • Adverse event leading to treatment discontinuation in TACTT2;
  • Meniere's Disease, endolymphatic hydrops, acoustic neuroma, severe or fluctuating hearing loss, otitis media, otitis externa, abnormality of tympanic membrane;
  • Ongoing drug-based therapy for otitis media or otitis externa;
  • Drug-based therapy known as potentially tinnitus-inducing;
  • Other treatment of tinnitus;
  • Drug abuse or alcoholism;
  • Subjects with psychiatric diseases requiring drug treatment;
  • Use of antidepressant or anti-anxiety medication;
  • Any clinically relevant disorder or abnormality in physical examination;
  • Women who are breast-feeding, pregnant or who are planning to become pregnant during the study;
  • Women of childbearing potential who are unwilling or unable to practice contraception.

Other protocol-defined exclusion criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
AM-101 injectionAM-101AM-101 gel for intratympanic injection
Primary Outcome Measures
NameTimeMethod
Frequency of Subjects With a Deterioration of Hearing Threshold at Day 119 (Air Conduction)Day 84 (TV4) to Day 119 (FUV5) of cycle 2

Valid for Safety Analysis Set was used.

Air conduction: The atmospheric transmission of sound to the inner ear through the external auditory canal and via structures of the middle ear. The ability of hearing is measured in decibel (dB). The hearing threshold, is the lowest sound pressure where the ear can perceive still a sound.

The endpoint deterioration of hearing threshold ≥15 dB in two contiguous test frequencies means that hearing worsens ≥15 dB in two neighboring sound frequencies.

Frequency of Subjects With a Deterioration of Hearing Threshold at Day 203 (Air Conduction)Day 168 (TV7) up to Day 203 (FUV8) of cycle 3

Valid for Safety Analysis Set was used.

Air conduction: The atmospheric transmission of sound to the inner ear through the external auditory canal and via structures of the middle ear. The ability of hearing is measured in decibel (dB). The hearing threshold, is the lowest sound pressure where the ear can perceive still a sound.

The endpoint deterioration of hearing threshold ≥15 dB in two contiguous test frequencies means that hearing worsens ≥15 dB in two neighboring sound frequencies.

Frequency of Subjects With a Deterioration of Hearing Threshold at Day 35 (Air Conduction)Day 1 (TV1) to Day 35 (FUV2) of cycle 1

Valid for Safety Analysis Set was used.

Air conduction: The atmospheric transmission of sound to the inner ear through the external auditory canal and via structures of the middle ear. The ability of hearing is measured in decibel (dB). The hearing threshold, is the lowest sound pressure where the ear can perceive still a sound.

The endpoint deterioration of hearing threshold ≥15 dB in two contiguous test frequencies means that hearing worsens ≥15 dB in two neighboring sound frequencies.

Secondary Outcome Measures
NameTimeMethod
Frequency of Subjects With a Deterioration of Hearing Threshold at Day 84 (Air Conduction)Day 1 (TV1) to Day 84 (FUV3) of cycle 1

Valid for Safety Analysis Set was used.

Air conduction: The atmospheric transmission of sound to the inner ear through the external auditory canal and via structures of the middle ear. The ability of hearing is measured in decibel (dB). The hearing threshold, is the lowest sound pressure where the ear can perceive still a sound.

The endpoint deterioration of hearing threshold ≥15 dB in two contiguous test frequencies means that hearing worsens ≥15 dB in two neighboring sound frequencies.

Frequency of Subjects With a Deterioration of Hearing Threshold at Day 168 (Air Conduction)Day 84 (TV4) to Day 168 (FUV6) of cycle 2

Valid for Safety Analysis Set was used.

Air conduction: The atmospheric transmission of sound to the inner ear through the external auditory canal and via structures of the middle ear. The ability of hearing is measured in decibel (dB). The hearing threshold, is the lowest sound pressure where the ear can perceive still a sound.

The endpoint deterioration of hearing threshold ≥15 dB in two contiguous test frequencies means that hearing worsens ≥15 dB in two neighboring sound frequencies.

Frequency of Subjects With a Deterioration of Hearing Threshold at Day 252 (Air Conduction)Day 168 (TV7) to Day 252 (FUV9) of cycle 3

Valid for Safety Analysis Set was used.

Air conduction: The atmospheric transmission of sound to the inner ear through the external auditory canal and via structures of the middle ear. The ability of hearing is measured in decibel (dB). The hearing threshold, is the lowest sound pressure where the ear can perceive still a sound.

The endpoint deterioration of hearing threshold ≥15 dB in two contiguous test frequencies means that hearing worsens ≥15 dB in two neighboring sound frequencies.

Trial Locations

Locations (1)

Medpace

🇺🇸

Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath